9 天on MSN
Recursion Pharmaceuticals Reports Positive Phase 1b/2 TUPELO Trial Results, Validating AI ...
Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion ...
10 天on MSN
Recursion Pharmaceuticals rises as positive Phase 1b/2 trial results for REC-4881 validate ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, ...
Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
DNA Ginkgo Bioworks Holdings, Inc.
1 天on MSNOpinion
The Memes Are the Point
These days, one doesn’t experience the news on these platforms before seeing the memes and reactions—the reaction and the ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果